WO2010046780A3 - Anti viral compounds - Google Patents

Anti viral compounds Download PDF

Info

Publication number
WO2010046780A3
WO2010046780A3 PCT/IB2009/007420 IB2009007420W WO2010046780A3 WO 2010046780 A3 WO2010046780 A3 WO 2010046780A3 IB 2009007420 W IB2009007420 W IB 2009007420W WO 2010046780 A3 WO2010046780 A3 WO 2010046780A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral compounds
anti viral
compounds
hts
hiv
Prior art date
Application number
PCT/IB2009/007420
Other languages
French (fr)
Other versions
WO2010046780A2 (en
Inventor
Junwon Kim
Jonathan Cechetto
Zaesung No
Thierry Christophe
Taehee Kim
Ji Youn Nam
Wonyoung So
Mina Jo
Taedong Ok
Changmin Park
Min Jung Seo
Jeong-Hun Sohn
Peter Sommer
Annette Sophia Boese
Sung-Jun Han
Young Sam Park
Hwa Pyung Kim
Original Assignee
Institut Pasteur Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur Korea filed Critical Institut Pasteur Korea
Publication of WO2010046780A2 publication Critical patent/WO2010046780A2/en
Publication of WO2010046780A3 publication Critical patent/WO2010046780A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided small molecule anti-human immunodeficiency virus (anti-HIV) compounds as well as a phenotypic cell-based high throughput screening (HTS) assay for their identification.
PCT/IB2009/007420 2008-10-22 2009-10-21 Anti viral compounds WO2010046780A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10744808P 2008-10-22 2008-10-22
US61/107,448 2008-10-22
US10902808P 2008-10-28 2008-10-28
US61/109,028 2008-10-28
US22883709P 2009-07-27 2009-07-27
US61/228,837 2009-07-27

Publications (2)

Publication Number Publication Date
WO2010046780A2 WO2010046780A2 (en) 2010-04-29
WO2010046780A3 true WO2010046780A3 (en) 2011-01-13

Family

ID=41820529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/007420 WO2010046780A2 (en) 2008-10-22 2009-10-21 Anti viral compounds

Country Status (1)

Country Link
WO (1) WO2010046780A2 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5775519B2 (en) * 2009-09-25 2015-09-09 ニヴァリス・セラピューティクス・インコーポレーテッド Novel dihydropyrimidin-2 (1H) -one compounds as S-nitrosoglutathione reductase inhibitors
ES2550939T3 (en) * 2010-07-16 2015-11-13 Nivalis Therapeutics, Inc. New dihydropyridin-2- (1H) -one compounds as S-nitrosoglutathione reductase inhibitors and neurocinin-3 receptor antagonists
US8906933B2 (en) 2010-09-24 2014-12-09 N30 Pharmaceuticals, Inc. Dihydropyrimidin-2(1H)-one compounds as neurokinin-3 receptor antagonists
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
JP2014527511A (en) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド TRPM8 antagonists and their use in therapy
CA2844119A1 (en) 2011-08-26 2013-03-07 Southern Research Institute Hiv replication inhibitors
ES2882807T3 (en) 2011-09-16 2021-12-02 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013091089A1 (en) * 2011-12-22 2013-06-27 UNIVERSITé LAVAL Three-dimensional cavities of dendritic cell immunoreceptor (dcir), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (hiv-1)
JP2013199459A (en) * 2012-03-26 2013-10-03 Konica Minolta Inc Method for producing cyanoacetic acid, method for producing cyanoacetic acid derivative and method for producing metal containing compound
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
CN105793255B (en) 2013-10-04 2018-11-16 无限药品股份有限公司 Heterocyclic compound and application thereof
MX2016007585A (en) * 2013-12-11 2016-12-16 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1.
MX2016006603A (en) 2013-12-20 2016-09-06 Esteve Labor Dr Piperidine compounds having multimodal activity against pain.
CN105849096B (en) 2013-12-20 2019-11-29 埃斯蒂文制药股份有限公司 The active piperidine derivative of multiplex mode with anti-pain
WO2015092009A1 (en) 2013-12-20 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Piperazine derivatives having multimodal activity against pain
JP6413790B2 (en) * 2014-02-05 2018-10-31 Jnc株式会社 Carbonyl derivatives, liquid crystal compositions containing these compounds, and liquid crystal display devices
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
ES2849998T3 (en) 2014-09-22 2021-08-24 National Health Res Inst Heterocyclic compounds and their use
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10179131B2 (en) * 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
TWI620748B (en) 2016-02-05 2018-04-11 National Health Research Institutes Aminothiazole compounds and use thereof
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CN105837564B (en) * 2016-03-30 2019-02-05 贵州大学 One kind benzothiazepines containing pyridine derivative, preparation method and the usage
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN108069955B (en) * 2016-11-14 2021-04-06 江苏恒瑞医药股份有限公司 3-pyridyl-4-benzothiazolylpyrazole derivatives, preparation method and medical application thereof
EP3570834B1 (en) 2017-01-11 2021-12-22 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-cyano-indazole compounds as hematopoietic progenitor kinase 1 (hpk1) modulators
US10047071B1 (en) 2018-01-15 2018-08-14 King Saud University Dihydropyrimidinone derivatives
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
MX2020008656A (en) 2018-02-20 2020-12-09 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer.
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (en) 2019-03-05 2021-01-01 美商英塞特公司 Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
ES2969616T3 (en) 2019-06-18 2024-05-21 Pfizer Benzisoxazole sulfonamide derivatives
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
CR20220066A (en) 2019-08-14 2022-11-28 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
TW202126640A (en) * 2019-09-29 2021-07-16 大陸商上海森輝醫藥有限公司 Method for preparing pyrroloaminopyridazinone compounds
PE20221905A1 (en) 2019-10-11 2022-12-23 Incyte Corp BICYCLIC AMINES AS INHIBITORS OF CDK2
PE20221040A1 (en) 2019-10-25 2022-06-17 Gilead Sciences Inc GLP-1R MODULATING COMPOUNDS
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
BR112023021561A2 (en) 2021-04-21 2023-12-19 Gilead Sciences Inc GLP-1R MODULATOR CARBOXY-BENZIMIDAZOLE COMPOUNDS
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN114957379B (en) * 2021-06-28 2024-03-26 河南省人民医院 Dihydropyrimidine thioketone compound and preparation method and application thereof
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114478396B (en) * 2022-03-18 2023-12-01 河南省人民医院 Dihydropyrimidine (thio) ketone compound, preparation method and application thereof
CN115093419B (en) * 2022-07-19 2023-08-04 徐州医科大学 Pyrimidinone compound, preparation method and medical application thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2711746A1 (en) * 1976-03-29 1977-10-06 Nippon Shinyaku Co Ltd NICOTINOYLAMINOTRIAZINE DERIVATIVES
JPH02129648A (en) * 1988-11-10 1990-05-17 Canon Inc Electrophotographic sensitive body
WO2002070484A1 (en) * 2001-03-05 2002-09-12 Bayer Aktiengesellschaft Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof
WO2002070520A1 (en) * 2001-03-07 2002-09-12 Bayer Aktiengesellschaft Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US20020156087A1 (en) * 1998-06-19 2002-10-24 Nuss John M. Inhibitors of glycogen synthase kinase 3
US20030064982A1 (en) * 2000-09-15 2003-04-03 Robert Davies Pyrazole compounds useful as protein kinase inhibitors
EP1302463A1 (en) * 2000-07-18 2003-04-16 Yamanouchi Pharmaceutical Co. Ltd. Medicine comprising dicyanopyridine derivative
WO2003049739A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
WO2004024691A1 (en) * 2002-09-16 2004-03-25 Glaxo Group Limited Cox-2 inhibiting pyridine derivatives
WO2004076412A2 (en) * 2003-02-26 2004-09-10 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
WO2005054199A1 (en) * 2003-12-03 2005-06-16 Cytopia Research Pty Ltd Tubulin inhibitors
WO2008033455A2 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
EP2141164A1 (en) * 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2346349A1 (en) * 1976-03-29 1977-10-28 Nippon Shinyaku Co Ltd NICOTINOYLAMINOTRIAZINE DERIVATIVES AND NEW PRODUCTS THUS OBTAINED FOR DIURETIC AND ANTI-ULCER ACTIVITIES
DE2711746A1 (en) * 1976-03-29 1977-10-06 Nippon Shinyaku Co Ltd NICOTINOYLAMINOTRIAZINE DERIVATIVES
JPH02129648A (en) * 1988-11-10 1990-05-17 Canon Inc Electrophotographic sensitive body
US20020156087A1 (en) * 1998-06-19 2002-10-24 Nuss John M. Inhibitors of glycogen synthase kinase 3
EP1302463A1 (en) * 2000-07-18 2003-04-16 Yamanouchi Pharmaceutical Co. Ltd. Medicine comprising dicyanopyridine derivative
US20030064982A1 (en) * 2000-09-15 2003-04-03 Robert Davies Pyrazole compounds useful as protein kinase inhibitors
WO2002070484A1 (en) * 2001-03-05 2002-09-12 Bayer Aktiengesellschaft Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof
WO2002070520A1 (en) * 2001-03-07 2002-09-12 Bayer Aktiengesellschaft Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2003049739A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
WO2004024691A1 (en) * 2002-09-16 2004-03-25 Glaxo Group Limited Cox-2 inhibiting pyridine derivatives
WO2004076412A2 (en) * 2003-02-26 2004-09-10 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
WO2005054199A1 (en) * 2003-12-03 2005-06-16 Cytopia Research Pty Ltd Tubulin inhibitors
WO2008033455A2 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
EP2141164A1 (en) * 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BRAD H. HENKE, DAVID H. DREWRY, STACEY A. JONES, EUGENE L. STEWART, SUSAN L. WEAVER, ROBERT W. WIETHE: "2-Amino-4,6-diarylpyridines as novel ligands for the estrogen receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 11, 2001, pages 1939 - 1942, XP002575776 *
BRITT-MARIE SWAHN, YAFENG XUE, ERWAN ARZEL, ELISABETH KALLIN, ANGELIKA MAGNUS ET AL: "Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 1397 - 1401, XP002575780 *
FENTON HEIRTZLER, MARKUS NEUBURGER, KLAUS KULIKE: "Insights on the synthesis and organisational phenomena of twisted pyrazine-pyridine hybrids", J. CHEM. SOC. PERKIN TRANSACTIONS 1, vol. 2002, no. 6, 2002, pages 809 - 820, XP002575779 *
FENTON R. HEIRTZLER: "Preparation of non-symmetrical 2,3-bis-(2,2'-oligopyridyl)pyrazines via 1,2-disubstituted ethanones", SYNLETT, vol. 1999, no. 8, 1999, pages 1203 - 1206, XP002575778 *
FRANCOISE GELLIBERT, ANNE-CHARLOTTE DE GOUVILLE, JAMES WOOLVEN, NEIL MATHEWS, VAN-LOC NGUYEN ET AL.: "Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A potent , selective and orally active transforming growth factor-beta type I receptor inhibitor", J. MED. CHEM., vol. 49, no. 7, 16 March 2006 (2006-03-16), pages 2210 - 2221, XP002575772 *
G. G. MOSKALENKO, V. F. SEDOVA: "Synthesis of substituted 2- and 4-hydroxyaminopyrimidines", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 22, no. 11, 1986, pages 1232 - 1236, XP002575774 *
ION NICOLESCU-DUVAZ, ESTEBAN ROMAN, STEVEN R. WHITTAKER, FRANK FRIEDLOS, RUTH KIRK ET AL: "Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead", J. MED. CHEM., vol. 49, no. 1, 2006, pages 407 - 416, XP002575784 *
ISABELLE PRÉVOT-HALTER, THOMAS I. SMITH, JEAN WEISS: "Assembling organic receptors around transition metal templates: Functionalized catechols and dioxomolybdenum(VI) for the recognition of dicarboxylic acids", J. ORG. CHEM., vol. 62, no. 7, 1997, pages 2186 - 2192, XP002575777 *
JOHN LIMANTO, RICHARD A. DESMOND, DONALD R. GAUTHIER, PAUL N. DEVINE, ROBERT A. REAMER, R. P. VOLANTE: "A regioselective approach to 5-substituted-3-amino-1,2,4-triazines", ORGANIC LETTERS, vol. 5, no. 13, 23 May 2003 (2003-05-23), pages 2271 - 2274, XP002575786 *
JULIO ALVAREZ-BUILLA, JUAN LOPEZ BENITO, MA. GLORIA QUINTANILLA: "Reinvestigation of Thesing's synthesis of 2-pyridones using 1-(methylthio-thiocarbonylmethyl)pyridinium iodide", J. PRAKT. CHEM., vol. 328, no. 2, 1986, pages 245 - 252, XP002575775 *
L. RUHLMANN, C. COSTA-COQUELARD, J. HAO, S. JIANG, C. HE, L. SUN, I. LAMPRE: "Association of ruthenium complexes [Ru(bpy)3]2+ or [Ru(bpy)2(Mebpy-py)]2+ with Dawson polyanions alpha-[P2W18O62]6- or alpha2-[FeIII(H2O)P2W17O61]7-", CAN. J. CHEM., vol. 86, no. 11, 15 October 2008 (2008-10-15), pages 1034 - 1043, XP002575782 *
MILES CONGREVE, DAVID AHARONY, JEFFREY ALBERT, OWEN CALLAGHAN, JAMES CAMPBELL ET AL: "Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase", J. MED. CHEM., vol. 50, no. 6, 2007, pages 1124 - 1132, XP002575785 *
ROLAND SPITZNER, MARKUS LESINSKI, MONIKA RICHTER, WERNER SCHROTH: "Nukleophile Substitutionen und Eliminierungen von Aminofunktionen via Pyridiniumsalze", MONATSHEFTE FÜR CHEMIE, vol. 118, 1987, pages 485 - 502, XP002575773 *
SANTOSH S. KULKARNI, AMY HAUCK NEWMAN: "Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 2074 - 2079, XP002575781 *
THOMAS BARK, THOMAS WEYHERMÜLLER, FENTON HEIRTZLER: "Self-assembly of a helical dicopper(I) metallophane", CHEM. COMMUN., vol. 14, 1998, pages 1475 - 1476, XP002575783 *

Also Published As

Publication number Publication date
WO2010046780A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
WO2010046780A3 (en) Anti viral compounds
WO2007134327A3 (en) Neutralizing antibodies to influenza viruses
EP2274335B8 (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
AU2009312751A8 (en) A screening assay for insecticides
EP3693734A3 (en) Mass spectrometry of steroidal compounds in multiplex samples
EP2310101A4 (en) Process for separating solids from valuable or harmful liquids by vaporisation
EP2365869A4 (en) Microporous membrane and method for forming
WO2008149345A3 (en) Tri-aryl compounds and compositions comprising the same
WO2011019986A3 (en) Processes for preparing pemetrexed
WO2006131936A3 (en) Hepatitis c virus vaccine
WO2010095041A3 (en) Compositions, methods, and kits for treating influenza viral infections
DK1348445T3 (en) Process for separating viruses from a protein solution by nano-filtration
WO2008095165A3 (en) Cell co-culture systems and uses thereof
WO2009112954A3 (en) Processes for the preparation of bosentan and related compounds
WO2011041646A3 (en) Method for sorting resistant seed from a mixture with susceptible seed
NZ596671A (en) Assays for influenza virus hemagglutinins
WO2002002738A3 (en) Host cells containing multiple integrating vectors
WO2007122517A3 (en) Influenza h5 pseudotyped lentiviruses and uses thereof
WO2013159094A3 (en) Improved processes for the preparation of 1-aryl-5-alkyl pyrazole compounds
WO2009024478A3 (en) Process for purifying polycrystalline silicon
WO2013074643A3 (en) Systems and methods to enhance consistency of assay performance
WO2008142379A3 (en) Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the s-isomer
Renu Maila anchal
WO2012174187A3 (en) Methods, compositions, and kits for determining human immunodeficiency virus (hiv)
WO2012087769A3 (en) A novel cell-based assay to identify polymerase inhibitors for viral infectious disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09756577

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09756577

Country of ref document: EP

Kind code of ref document: A2